Filing Flows

Filing Flows › Companies › Pulmatrix › Cash flow

Pulmatrix cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$1.1M in Q2 2026 · −$3.9M over twelve months

Operating cash flow−$1.1M
Free cash flow−$1.1M

Analysis

In Q2 2026, Pulmatrix generated −$1.1M of operating cash flow. That is $777K more than in Q2 2025 (−$1.9M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$3.9M; the largest uses were operating cash flow ($3.9M); the cash balance fell by $3.0M.

Operating cash flow was −$1.1M against net income of −$1.0M. The largest differences: payables −$122K, prepaid and other assets +$94K, accrued liabilities −$44K.

Free cash flow

Pulmatrix: free cash flow by quarterPulmatrix: free cash flow by quarter−$3.1MQ3 2024−$1.3MQ4 2024−$1.8MQ1 2025−$1.9MQ2 2025−$1.0MQ3 2025−$706KQ4 2025−$1.1MQ1 2026−$1.1MQ2 2026
Operating cash flow less capital spending.
Pulmatrix: operating cash flow against capital spendingPulmatrix: operating cash flow against capital spendingOperating cash flowCapital spending−$3.1M$0Q3 2024−$1.3M$0Q4 2024−$1.8M$0Q1 2025−$1.9M$0Q2 2025−$1.0M$0Q3 2025−$706K$0Q4 2025−$1.1M$0Q1 2026−$1.1M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$1.1M, Capital spending $0.

Capital allocation, year by year

Pulmatrix: where the cash came from (up) and went (down), by fiscal yearPulmatrix: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$19.7MFY2021: Shares issued $37.1MFY2021: Capital spending −$144K$37.1MFY2021FY2022: Operating cash flow −$19.4MFY2022: Shares issued $1.4MFY2022: Capital spending −$86K$1.4MFY2022FY2023: Operating cash flow −$16.0MFY2023: Shares issued $53KFY2023: Capital spending −$676K$53KFY2023FY2024: Operating cash flow −$10.7MFY2024: Capital spending −$398KFY2024FY2025: Operating cash flow −$5.4MFY2025
Over these 5 years operating cash flow totalled −$71.2M; the largest uses were operating cash flow ($71.2M) and capital spending ($1.3M). Cash-flow statements as filed.

Where the cash came from and went

Pulmatrix: sources (+) and uses (−) of cash, Q2 2026Pulmatrix: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$1.2MOperating cash flow−$1.1MOther financing−$50K
Pulmatrix: sources (+) and uses (−) of cash, TTM to Q2 2026Pulmatrix: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$3.9MCash drawn (+) / kept (−)$3.0MNot reconciled$950K

From profit to cash

Pulmatrix: net income to operating cash flow, Q2 2026Pulmatrix: net income to operating cash flow, Q2 2026Net income−$1.0MStock-based pay$2KPayables−$122KAccrued liabilities−$44KPrepaid and other assets$94KOperating cash flow−$1.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$1.1M—$1.2M−$1.1M
Q1 2026−$1.1M$1.0M$67K−$1.1M
Q4 2025−$706K—$706K−$706K
Q3 2025−$1.0M—$1.0M−$1.0M
Q2 2025−$1.9M—$1.9M−$1.9M
Q1 2025−$1.8M—$1.8M−$1.8M
Q4 2024−$1.3M—$1.3M−$1.3M
Q3 2024−$3.1M—$3.1M−$3.1M

Pulmatrix: income statement and cash flow

Pulmatrix, Q4 2024: revenue $3K (-100% year over year). The chart follows the revenue to costs, profit and cash.

Pulmatrix: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.